ARCHIVES

“Spoiled, Petulant Brat”: BioMarin CEO Fires Off Feisty Emails In Battle Over Access to PARP Inhibitor

This article is from The Cancer Letter archive.

Vol. 39 No. 42 | November 8, 2013

Download PDF Visit The Full Archive

Related Articles

As FDA Weighs its Options on Morcellation, Debate Erupts Over Harvard Device Study

November 21, 2014

NCAB Working Group Renamed, Adds Karen Antman

December 16, 1994

Immunotherapy Demonstrates Disease Control in Phase II Study

September 28, 2012

Responses So Far Support Outstanding Investigator Grant; NCAB Members Object To Salary commitment

July 8, 1983

Von Eschenbach Takes NCI’s Helm As Bush Proposes Budget Increase.

February 8, 2002

Blood Donors With Undertrain HTLV-3 Should Be Notified, Consensus Panel Says

July 18, 1986